The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
33046366
DOI
10.1016/j.urolonc.2020.09.005
PII: S1078-1439(20)30436-1
Knihovny.cz E-resources
- Keywords
- Abiraterone, Docetaxel, Enzalutamide, MMP-7, Prostate cancer,
- MeSH
- Androstenes therapeutic use MeSH
- Benzamides therapeutic use MeSH
- Docetaxel therapeutic use MeSH
- Adult MeSH
- Phenylthiohydantoin therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Matrix Metalloproteinase 7 blood MeSH
- Survival Rate MeSH
- Prostatic Neoplasms, Castration-Resistant blood drug therapy mortality MeSH
- Nitriles therapeutic use MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- abiraterone MeSH Browser
- Androstenes MeSH
- Benzamides MeSH
- Docetaxel MeSH
- enzalutamide MeSH Browser
- Phenylthiohydantoin MeSH
- Matrix Metalloproteinase 7 MeSH
- Nitriles MeSH
- Antineoplastic Agents MeSH
OBJECTIVES: The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy. Here, we aimed to test this finding in an independent patient cohort and in addition to explore the prognostic potential of serum MMP-7 in abiraterone (ABI) or enzalutamide (ENZA) treated patients. METHODS AND MATERIALS: MMP-7 levels were measured in 836 serum samples from 320 mCRPC patients collected before and during DOC (n = 95), ABI (n = 140), or ENZA (n = 85) treatment by using the ELISA method. Results were correlated with clinical and follow-up data. RESULTS: MMP-7 baseline levels were similar between the 3 treatment groups. In the ABI and ENZA cohorts, baseline MMP-7 levels were lower in patients with prior radical prostatectomy (P = 0.058 and P = 0.041, respectively). Baseline MMP-7 levels above the median were associated with shorter overall survival for the DOC (P = 0.001) and ENZA (P = 0.006) cohorts. Multivariable analyses in the DOC and ENZA cohorts revealed that high pretreatment MMP-7 level is an independent risk factor for patients' survival. In addition, in DOC-treated patients with high baseline MMP-7 level, marker decrease at the third DOC cycle was associated with improved survival. Patients with high baseline MMP-7 levels had better survival when treated with ABI compared to DOC or ENZA. CONCLUSIONS: We confirmed the prognostic value of pretreatment MMP-7 serum level and its changes as independent predictors of survival in DOC-treated mCRPC patients. In addition, high MMP-7 was a negative predictor in ENZA-treated but not in ABI-treated patients. These results warrant further research to confirm the predictive value of serum MMP-7 and to explore the potential mechanistic involvement of MMP-7 in DOC and ENZA resistance of mCRPC patients.
Department of Urology Comprehensive Cancer Centre Medical University of Vienna Vienna Austria
Department of Urology Faculty of Medicine University of Duisburg Essen Essen Germany
Department of Urology Semmelweis University Budapest Hungary
References provided by Crossref.org
